MannKind CorporationMNKD stock score: 56/100
$3.95 · -2.95% · Scored Nov 19, 2026
- Technical
- 43
- Fundamental
- 59
- News
- 52
The reading
MannKind (MNKD) scores 56 out of 100, which reads neutral, higher than 64% of Healthcare stocks and 63% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 59, technicals 43.
Among the fundamentals, Price Target at 100 and Revenue Growth (5-Year) at 97 score highest, while Earnings Quality (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 56 and contrarian oscillators 42.
News sentiment is neutral at 52; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 37 to 58, and it is up 9 points over the period.
About MannKind
MannKind (MNKD) is a biopharmaceutical company that develops and makes inhaled therapies and other treatments for endocrine and cardiopulmonary diseases. Its Technosphere dry-powder inhalation platform is the basis for Afrezza, an inhaled mealtime insulin approved for adults with diabetes and more recently for children, which MannKind sells in the United States. It also makes Tyvaso DPI, an inhaled form of treprostinil for pulmonary hypertension, for United Therapeutics, earning manufacturing revenue and royalties on its sales. Through its acquisition of scPharmaceuticals, MannKind sells FUROSCIX, a furosemide treatment given under the skin at home to relieve fluid buildup in patients with heart failure or chronic kidney disease. Its pipeline includes inhaled versions of nintedanib for idiopathic pulmonary fibrosis and other lung diseases. MannKind earns money from product sales, royalties and contract manufacturing.
MannKind competes with Novo Nordisk, Eli Lilly and Sanofi in insulin, while Tyvaso DPI competes with Liquidia’s Yutrepia and other pulmonary hypertension drugs, and FUROSCIX competes mainly with hospital and oral diuretic treatment. Its edge rests on proprietary inhalation technology, manufacturing capability and a royalty stream that supports its own launches. Investors who follow MNKD stock tend to watch Tyvaso DPI royalties and FUROSCIX sales growth. Afrezza adoption, including in children, is closely followed. Pipeline data, operating costs and debt levels are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward MNKD’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
59Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
5-year revenue growth analyzes long-term sales trajectory and consistency.
Annual revenue growth tracks year-over-year sales expansion.
Holding it back
How often the company beat analysts' EPS estimates over recent quarters, by how much, and the trend in reported EPS from quarter to quarter.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Net income growth from the prior fiscal year to the latest.
35 weighted scorers; 4 had no data today and are left out rather than counted as zero.
Technical · daily
55Pulling it up
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Performance versus SPY compares the stock's returns to the S&P 500 index.
Know Sure Thing (KST) combines multiple rate-of-change calculations to identify long-term trend reversals.
Holding it back
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
SPY SMA 50 tracks the S&P 500 (SPY) position relative to its 50-period moving average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 52
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 38 | 1 |
| Daily | 55 | 3 |
| Weekly | 42 | 2 |
| Monthly | 34 | 2 |
| Quarterly | 37 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 56 |
| Nov 18, 2026 | 57 |
| Nov 17, 2026 | 57 |
| Nov 16, 2026 | 56 |
| Nov 15, 2026 | 57 |
| Nov 14, 2026 | 57 |
| Nov 13, 2026 | 57 |
| Nov 12, 2026 | 58 |
| Nov 11, 2026 | 48 |
| Nov 10, 2026 | 49 |
| Nov 8, 2026 | 46 |
| Nov 7, 2026 | 47 |
| Nov 6, 2026 | 45 |
| Nov 5, 2026 | 42 |
| Nov 4, 2026 | 47 |
| Nov 3, 2026 | 45 |
| Nov 2, 2026 | 44 |
| Nov 1, 2026 | 42 |
| Oct 30, 2026 | 42 |
| Oct 29, 2026 | 42 |
| Oct 28, 2026 | 41 |
| Oct 27, 2026 | 40 |
| Oct 26, 2026 | 40 |
| Oct 25, 2026 | 40 |
| Oct 24, 2026 | 40 |
| Oct 23, 2026 | 39 |
| Oct 22, 2026 | 39 |
| Oct 21, 2026 | 38 |
| Oct 20, 2026 | 38 |
| Oct 19, 2026 | 38 |
| Oct 18, 2026 | 38 |
| Oct 17, 2026 | 38 |
| Oct 16, 2026 | 37 |
| Oct 15, 2026 | 39 |
| Oct 14, 2026 | 38 |
| Oct 13, 2026 | 37 |
| Oct 12, 2026 | 38 |
| Oct 11, 2026 | 38 |
| Oct 10, 2026 | 38 |
| Oct 9, 2026 | 38 |
| Oct 8, 2026 | 38 |
| Oct 7, 2026 | 39 |
| Oct 6, 2026 | 43 |
| Oct 5, 2026 | 43 |
| Oct 4, 2026 | 45 |
| Oct 3, 2026 | 45 |
| Oct 2, 2026 | 44 |
| Oct 1, 2026 | 46 |
| Sep 30, 2026 | 44 |
| Sep 29, 2026 | 39 |
| Sep 28, 2026 | 39 |
| Sep 27, 2026 | 39 |
| Sep 26, 2026 | 39 |
| Sep 25, 2026 | 39 |
| Sep 24, 2026 | 39 |
| Sep 23, 2026 | 39 |
| Sep 22, 2026 | 39 |
| Sep 21, 2026 | 40 |
| Sep 20, 2026 | 39 |
| Sep 19, 2026 | 39 |
| Sep 18, 2026 | 39 |
| Sep 17, 2026 | 39 |
| Sep 16, 2026 | 38 |
| Sep 15, 2026 | 38 |
| Sep 14, 2026 | 41 |
| Sep 13, 2026 | 41 |
| Sep 12, 2026 | 41 |
| Sep 11, 2026 | 41 |
| Sep 10, 2026 | 41 |
| Sep 9, 2026 | 44 |
| Sep 8, 2026 | 47 |
| Sep 7, 2026 | 44 |
| Sep 6, 2026 | 44 |
| Sep 5, 2026 | 44 |
| Sep 4, 2026 | 43 |
| Sep 3, 2026 | 43 |
| Sep 2, 2026 | 45 |
| Sep 1, 2026 | 44 |
| Aug 31, 2026 | 43 |
| Aug 30, 2026 | 43 |
| Aug 29, 2026 | 43 |
| Aug 28, 2026 | 42 |
| Aug 27, 2026 | 44 |
| Aug 26, 2026 | 46 |
| Aug 25, 2026 | 47 |
| Aug 24, 2026 | 46 |
| Aug 23, 2026 | 47 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.09
- Risk grade (1–10)
- 3
- Next earnings
- Nov 5, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| INVA Innoviva | $1.3B | 63 |
| LBRX LB Pharmaceuticals | $1.3B | 41 |
| OCUL Ocular Therapeutix | $1.3B | 38 |
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
| MLYS Mineralys Therapeutics | $1.3B | 31 |
Questions
What is MNKD's stock rating today?
MNKD scores 56/100 (Neutral) as of Nov 19, 2026: technical 43, fundamental 59, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.
What does MannKind do?
MannKind (MNKD) is a biopharmaceutical company that develops and makes inhaled therapies and other treatments for endocrine and cardiopulmonary diseases. Its Technosphere dry-powder inhalation platform is the basis for Afrezza, an inhaled mealtime insulin approved for adults with diabetes and more recently for children, which MannKind sells in the United States.
Is MNKD stock a buy?
The score is not a buy or sell recommendation. A 56 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the MNKD score calculated?
97 weighted scorers feed it today: 35 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/mnkd/"><img src="https://stocksscores.com/stocks/mnkd/badge.svg" alt="MNKD stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/mnkd/)